Chinese biotechs are rushing to raise cash through the public market as investor sentiment has improved.
Shanghai-based InventisBio, Inc., a developer of small molecule cancer and gout drugs has become the latest biotech to do...
Three Chinese Biotechs Ride Market Recovery To Raise Funds
InventisBio and Akeso seek to gross a combined $384.3m in an initial public share sale in Shanghai and a private placement in Hong Kong respectively, while Chipscreen completed raising $74.4m by selling convertible bonds in Shanghai.
